Genetic test reduces warfarin-related hospitalization, study finds

03/16/2010 | Bloomberg Businessweek

Patients who had genetic testing for expression of genes CYP2C9 and VKORC1, which indicate sensitivity to blood thinner warfarin, were less likely to be hospitalized for bleeding, thromboembolism or other reasons during the first six months of taking the drug than those who did not have genetic testing, according to a study. "If we reduce just two hospitalizations per 100 patients tested, that more than compensates for the cost of genotyping," an expert said.

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Food & Drug Associate
Confidential
Washington, D.C., DC